Patents by Inventor Cynthia A. Edwards

Cynthia A. Edwards has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180243517
    Abstract: This disclosure includes elbow braces for intravenous therapy and related methods. Some braces have a rigid frame, wherein the frame includes: a width and a length longer than the width; a first end having a first surface configured to contact an arm of a patient and a second end spaced along the length from the first end and having a second surface configured to contact the arm, wherein the second surface is configured to be disposed at an angle relative to the first surface that is between approximately 10 degrees and 45 degrees; and an opening extending through the frame; and a cushion configured to be disposed onto at least a portion of a peripheral edge of the frame.
    Type: Application
    Filed: February 28, 2017
    Publication date: August 30, 2018
    Inventor: Cynthia Edwards
  • Patent number: 7189506
    Abstract: The present invention provides molecular switch system methods and compositions for use in regulatable gene expression. The system includes a nucleic acid construct which has a DNA response sequence for a transcriptional regulatory protein operably linked to a promoter, a compound binding sequence in the vicinity of the DNA response sequence, a transgene under the control of the promoter; and a DNA binding compound. In some cases, the molecular switch system further includes a nucleic acid sequence encoding a transcriptional regulatory protein operably linked to a second promoter. The invention further provides a method for screening compounds for the ability to function in the molecular switch system and thereby regulate gene expression.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: March 13, 2007
    Assignee: Genelabs Technologies, Inc.
    Inventors: Moon Young Lim, Cynthia A. Edwards, Kirk E. Fry, Thomas W. Bruice, Douglas B. Starr, Megan E. Laurance, Yan Kwok, Albert W. Tam
  • Publication number: 20060141456
    Abstract: The present invention provides methods and compositions for milieu-dependent binding of a targeted agent to a target, for example, for the milieu-dependent binding of a diagnostic or therapeutic molecule to a diseased, injured or infected organ, tissue or cell.
    Type: Application
    Filed: June 9, 2003
    Publication date: June 29, 2006
    Inventors: Cynthia Edwards, Judith Fox, Christopher Murray, Volker Schellenberger, Robert Tressler
  • Patent number: 6869765
    Abstract: The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: March 22, 2005
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
  • Publication number: 20030124530
    Abstract: The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.
    Type: Application
    Filed: November 13, 2001
    Publication date: July 3, 2003
    Applicant: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
  • Publication number: 20030049689
    Abstract: The present invention provides methods and compositions relating to polypeptides engineered to bind a target and have at least two functional domains.
    Type: Application
    Filed: June 12, 2002
    Publication date: March 13, 2003
    Inventors: Cynthia Edwards, Volker Schellenberger, Christopher J. Murray, Yiyou Chen, Anthony G. Day
  • Patent number: 6384208
    Abstract: The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: May 7, 2002
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
  • Patent number: 6010849
    Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 4, 2000
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
  • Patent number: 5869241
    Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 9, 1999
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
  • Patent number: 5744131
    Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 28, 1998
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
  • Patent number: 5738990
    Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 14, 1998
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
  • Patent number: 5726014
    Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.
    Type: Grant
    Filed: September 17, 1993
    Date of Patent: March 10, 1998
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin
  • Patent number: 5716780
    Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 10, 1998
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
  • Patent number: 5693463
    Abstract: The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.
    Type: Grant
    Filed: December 23, 1992
    Date of Patent: December 2, 1997
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Kirk E. Fry, Charles R. Cantor, Beth M. Andrews
  • Patent number: 5578444
    Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.
    Type: Grant
    Filed: December 20, 1993
    Date of Patent: November 26, 1996
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
  • Patent number: 5306619
    Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Also described herein is a method to capture DNA that has been released from the DNA:protein complex.
    Type: Grant
    Filed: June 22, 1993
    Date of Patent: April 26, 1994
    Assignee: Genelabs Technologies, Inc.
    Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews